Dr. Kenneth S. Sharlin, MD
Neurology (Neurology Physician)
5528 N Farmer Branch Rd
Ozark, MO 65721
Who else practices at this address →
Christian County is a federal primary care and dental shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Emory University School of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 214
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Emory University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
MO license 2000160886 -
Internal Medicine Physician
MO license 2000160886
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cox Medical Centers Springfield, MO
- Cox Medical Center Branson Branson, MO
Medical groups
- Sharlin Health and Neurology LLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 214
- Services billed
- 595
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 271 | 147 |
| New patient office or other outpatient visit, 60-74 minutes | 55 | 55 |
| Established patient office or other outpatient visit, 10-19 minutes | 53 | 18 |
| Established patient office or other outpatient visit, 20-29 minutes | 52 | 47 |
| Evaluation of neuropsychological test, first hour | 15 | 15 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Progesterone (progesterone, micronized) Other prescribers in Ozark, MO | 307 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Ozark, MO | 238 |
| Levetiracetam Other prescribers in Ozark, MO | 97 |
| Pregabalin Other prescribers in Ozark, MO | 97 |
| Estradiol Other prescribers in Ozark, MO | 94 |
| Lamotrigine Other prescribers in Ozark, MO | 86 |
| Donepezil Hcl Other prescribers in Ozark, MO | 85 |
| Duloxetine Hcl Other prescribers in Ozark, MO | 84 |
| Aimovig Autoinjector (erenumab-aooe) Other prescribers in Ozark, MO | 80 |
| Primidone Other prescribers in Ozark, MO | 77 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 28 companies reported 95 payments worth $3,115 in total to this clinician.
| Food and Beverage | $1,938 |
|---|---|
| Travel and Lodging | $1,177 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Jul 22, 2025 | Travel and Lodging travel to Atlanta, GA · in-kind | $1,177 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 7 companies. The companies reported $314,638 in research payments for these studies, mostly to the institutions running them.
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141473 - A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
Eli Lilly and Company · Terminated · NCT06220669 - Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Genzyme Corporation · Completed · NCT04458051 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease
E.r. Squibb & Sons, L.l.c. - A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis
Hoffmann-la Roche Limited - Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141486 - A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
ModernaTX, Inc. · Recruiting · NCT06735248 - A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Genzyme Corporation · Active, not recruiting · NCT06372145 - Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
Genzyme Corporation · Completed · NCT04410978 - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.